Released Sep 14, 2020, after the close
10-Q filed Sep 14, 2020, 45 days after period end · 0001654954-20-010065
Q3 2020 · 10-Q
Revenue$6.28M$6.28M +26.4% vs Q3 2019+11.2% vs Q2 2020
Net Income$692.11K$692.11K +60.5% vs Q3 2019+0.7% vs Q2 2020
EPS, diluted—
Gross Profit$1,854,219+18.4%
Operating Income$816,690+126.4%
Operating Cash Flow$1,219,735N/M
Free Cash Flowderived$1,209,273N/M
Margins · derived
Gross margin29.5%−2.0 pt vs Q3 2019
Operating margin13.0%+5.7 pt vs Q3 2019
Net margin11.0%+2.3 pt vs Q3 2019
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $6.28M | $4.97M | $4.63M | $3.98M |
| Net Income | $692.11K | $431.16K | $730.63K | -$162.98K |
| EPS Diluted | — | — | $0.03 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR